NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/18/2025
Back to search
Official data from USPTO
CYTOTIL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
11/19/2025
Classification
Registered
Trademark type
Word
Nice classes
42
Filing date
05/10/2023
Registration date
11/18/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/18/2025
Last transaction
11/19/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
2019-10-00
First use in commerce
2019-10-00
Drawing code
4
Owner type
03
Owner location
Cambridge, MA
Examiner
SMITH,BRENDAN K
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Obsidian Therapeutics, Inc.
Representatives
Olivia Maria Baratta KILPATRICK TOWNSEND & STOCKTON LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
medical and scientific research and development services in the fields of cell therapygene therapyoncologyimmunotherapy
Publications
History of USPTO decisions and trademark events.
39 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
11/18/2025
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
10/16/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
09/26/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/26/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
09/26/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/26/2025
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
07/09/2025
GNSF
SUBSEQUENT FINAL EMAILED
07/09/2025
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
07/09/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/21/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/21/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/21/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
02/19/2025
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
02/19/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/21/2024
GNRT
NON-FINAL ACTION E-MAILED
11/21/2024
CNRT
NON-FINAL ACTION WRITTEN
11/21/2024
IUAA
USE AMENDMENT ACCEPTED
11/21/2024
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
10/17/2024
IUAF
USE AMENDMENT FILED
10/17/2024
EAAU
TEAS AMENDMENT OF USE RECEIVED
10/17/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/17/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
05/23/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
05/23/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/17/2024
GNFR
FINAL REFUSAL E-MAILED
04/17/2024
CNFR
FINAL REFUSAL WRITTEN
04/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/18/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/18/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/18/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
12/14/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
12/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/18/2023
GNRT
NON-FINAL ACTION E-MAILED
09/18/2023
CNRT
NON-FINAL ACTION WRITTEN
09/18/2023
DOCK
ASSIGNED TO EXAMINER
09/14/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/08/2023
NWAP
NEW APPLICATION ENTERED
05/13/2023
Continuous trademark protection
Get notified about every new filing that threatens CYTOTIL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.